Company news

Jiangsu Kanion Pharmaceutical Co. Ltd. news in 2025

Jiangsu Kanion Pharmaceutical Co. Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

December 29, 2025

Announcement on Obtaining the Drug Registration Certificate for Xiebai San Granules

December 12, 2025

Announcement on Cancelling the Board of Supervisors and Amending the Articles of Association and Some Governance Systems

December 11, 2025

Announcement on Shareholding Increase Result of Some Directors and Senior Management Members

December 9, 2025

Announcement on the Inclusion of the Company’s Partial Drugs in the National Medical Insurance Catalog

December 8, 2025

江苏康缘药业股份有限公司关于实际控制人、董事增持公司股份的公告

November 18, 2025

Announcement on Shareholding Increase by Persons Acting in Concert of Actual Controllers

November 12, 2025

Announcement on Voluntary Shareholding Increase Plan by Certain Directors and Senior Management Members

November 7, 2025

Report for Q3 2025

October 30, 2025

Announcement on Wholly-owned Subsidiary's Drug Additional Indication Obtaining Clinical Trial Approval Notice

October 29, 2025

Announcement on Pledge of Some Shares Held by Shareholders with Over 5% Shares

September 26, 2025

2025 Semi-annual Report

August 27, 2025

Announcement on the Receipt of the Clinical Trial Approval Notice for Jinzhen Oral Liquid with Increased Indications

August 22, 2025

Announcement on the Receipt of the Clinical Trial Approval Notice for Jianpi Shugan Guben Granules

August 18, 2025

Announcement on Obtaining Drug Registration Certificate for Shenpu Granules

August 3, 2025

Announcement on the Receipt of the Clinical Trial Approval Notice for KYS2301 Gel

July 3, 2025

Announcement on Outgoing of Chairman

June 20, 2025

Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License

June 10, 2025

Announcement on Passive Increase in Shareholding Ratio of Controlling Shareholder Due to Repurchase and Cancellation of Restricted Stocks by the Company Touching an Integer Multiple of 1%

May 30, 2025

Announcement on Implementing Repurchase and Cancellation of All Remaining Restricted Stocks under the 2022 Annual Restricted Stocks Incentive Plan

May 26, 2025

Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing

May 20, 2025

Announcement on Main Operating Data for Q1 2025

April 29, 2025

Announcement Obtaining Drug Registration Certificate for Gypsum Decoction Granules

April 27, 2025

Announcement on Resolutions of the 2024 Annual General Meeting

April 24, 2025

Announcement on Resolutions of the 16th Meeting of the 8th Board of Directors

April 2, 2025

Announcement on Receiving the Notice of Approval for Clinical Trials of Lianshen Gengnian Granules

March 27, 2025

Announcement on Receiving the Notice of Approval for Clinical Trials of Guben Xiaozhen Granules

March 4, 2025

Announcement on the Completion of Shareholding Increase Plan by Persons Acting in Concert with Controlling Shareholders and Results of the Increase

February 26, 2025

Announcement on Progress in Shareholding Increase by Persons Acting in Concert with Controlling Shareholders and Subsequent Shareholding Increase Plan

February 24, 2025

Announcement on Implementation Results of Share Repurchase and Share Changes

February 5, 2025

Announcement on Resignation and By-election of Independent Director

December 31, 2024